An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.

Area of Science:

• Nephrology
• Immunology
• Biochemistry

Background:

• Abnormal complement alternative pathway regulation is implicated in C3 glomerulopathy.
• Complement factor H (CFH) is a critical plasma regulator of this pathway, but producing full-length recombinant CFH is challenging.
• Mini-complement factor H proteins are being developed to overcome production difficulties.

Purpose of the Study:

• To evaluate the in vitro and in vivo efficacy of a novel mini-complement factor H protein, FH^{1-5^18-20}.
• To assess FH^{1-5^18-20}'s therapeutic potential in a mouse model of C3 glomerulopathy.

Main Methods:

• Utilized a unique factor H-deficient (Cfh-/-) mouse model of C3 glomerulopathy.
• Administered FH^{1-5^18-20} via intraperitoneal injection.
• Assessed glomerular C3 deposition and systemic alternative pathway control.

Main Results:

• FH^{1-5^18-20} significantly reduced abnormal glomerular C3 deposition in Cfh-/- mice, comparable to full-length factor H.
• Systemic control of the alternative pathway by FH^{1-5^18-20} was modest, likely due to its short half-life.
• The engineered protein comprises key regulatory (SCRs 1-5) and surface recognition (SCRs 18-20) domains.

Conclusions:

• FH^{1-5^18-20} demonstrates therapeutic promise for C3 glomerulopathy.
• This mini-factor H protein may also benefit other renal conditions involving alternative pathway-mediated injury.
• Further investigation into optimizing its pharmacokinetic profile may enhance efficacy.